Medtronic plc, the global leader in medical technology, today announced its participation at the American Diabetes Association (ADA) 82^nd scientific sessions virtual meeting, June 3-7, 2022. Medtronic will showcase outcomes for the MiniMed™ 780G System with Guardian™ 4 sensor, the Advanced Hybrid Closed-Loop insulin delivery system, and build awareness and understanding of the Medtronic Extended infusion set and InPen™ Smart insulin pen. The company will sponsor events and exhibits on diabetes technology, clinical outcomes, and support offerings for healthcare professionals and patients throughout the meeting.

Scientific Presentations
The following poster and oral scientific data presentations represent the work of Medtronic employees and independent investigators using Medtronic devices in their research. Poster presentations will be available to all attendees for viewing throughout the conference.

Advanced Hybrid Closed-Loop Data Presentations

• “Results of treatment satisfaction and fear of hypoglycemia in the ADAPT study: A 6-month, randomized controlled trial comparing an advanced hybrid closed-loop system (MiniMed 780G system) to multiple daily injections (MDI) with intermittently scanned CGM (isCGM)” – poster presentation (770-P) on Sunday, June 5 at 12:00 p.m. CT by Ohad Cohen, M.D., Senior Global Medical Affairs Director, Medtronic Diabetes (authored by Simona De Portu, Reimbursement, Health Economics and Government Affair Director, Medtronic Diabetes).
• “Real-world use of the MiniMed™ 780G system with the Guardian sensor 3 and the Guardian™ 4 sensor” – poster presentation (763-P) by Robert A. Vigersky, M.D., Chief Medical Officer, Medtronic Diabetes, on Sunday, June 5 at 12:00 p.m. CT.
• “Performance of the MiniMed™ 780G System with the Guardian 4 Sensor: Impact on the First 1,570 Real-world Users” – poster presentation (760-P) on Sunday, June 5 at 12:00 p.m. CT, ePoster Presentation on Saturday, June 4 at 12:30 p.m. CT by John Shin, Ph.D., MBA, Senior Clinical Research Director, Medtronic Diabetes.
• “Glycemic outcomes after six months of real-world use of MiniMed 780G advanced hybrid closed-loop (AHCL) therapy by individuals with type 1 diabetes (T1D) in Chile” – poster presentation (776-P) on Sunday, June 5 at 12:00 p.m. CT by Matias Castro, M.Phil., Principal Medical Liaison Specialist, Medtronic Diabetes.
• “Effect of optimized MiniMed 780G advanced hybrid closed-loop (AHCL) therapy settings in Chile: Real-world glycemic outcomes after 6 months of use” – poster presentation (775-P) on Sunday, June 5 at 12:00 p.m. CT by Matias Castro.
• “Glycemic Control Using Recommended Settings in Youth and Adults with Type 1 Diabetes (T1D)—Minimed 780G System with the Calibration-Free Guardian 4 Sensor Results” – late-breaking poster presentation (100-LB) on Sunday, June 5 at 12:00 p.m. CT by Robert A. Vigersky, M.D.
• “Complex meal handling with the advanced hybrid closed-loop (AHCL) system” – poster presentation (554-P) by Maya Laron Hirsh, B.Sc., Sheba Medical Center.
• “Announced Meals at-will with the MiniMed™ 780G advanced hybrid closed-loop (AHCL) system” – poster presentation (779-P) on Sunday, June 5 at 12:00 p.m. CT, by Noga Minsky, M.D., Sheba Medical Center.
• “Eliminating manual meal bolusing: A feasibility trial using MiniMed 780G and hand gesture algorithms” – oral presentation (287-OR) on Monday, June 6 at 2:30 p.m. CT by Anirban Roy, Ph.D., Distinguished Scientist, Medtronic Diabetes.

Infusion Set Data Presentations

• “An insulin infusion set with novel kink-free flexible cannula: In-vitro/in-vivo studies” – poster presentation (784-P) on Sunday, June 5 at 12:00 p.m. CT by Chia Chiu, Research & Technology Engineering Director, Medtronic Diabetes.
• “Development of an extended-wear infusion set with angled cannula” – poster presentation (788-P) on Sunday, June 5 at 12:00 p.m. CT by Sarnath Chattaraj, Ph.D., senior research director, Medtronic Diabetes (authored by Gina Zhang, Ph.D., Senior Principal Scientist, Medtronic Diabetes).

Health Equity Data Presentations

• “Racial and ethnic inequities in use of diabetes technology among Medicare Advantage beneficiaries with type 1 diabetes” – poster presentation (1264-P) on Saturday, June 4 at 11:30 a.m. CT by Mallika Kommareddi, MPH, Principal Health Economics & Outcomes Research Specialist, Medtronic Diabetes.

InPen Data Presentations

• “Decision tree modeling identifies factors associated with increased time-in-range (TIR) during InPen smart insulin pen and continuous glucose monitoring (CGM) use in youth” – late-breaking poster presentation (152-LB) on Sunday, June 5 at 12:00 p.m. CT by Madison B. Smith, Ph.D., R.N., CDCES, R&D Clinical Product Manager, Medtronic Diabetes.

Medtronic Sponsored Events
Medtronic will host a live LinkedIn virtual event for conference and non-conferences attendees, as well as an exhibit booth with in-booth presentations, a product theater, and an innovation suite.  

• LinkedIn Livestream: A discussion with Que Dallara, EVP & President, Medtronic Diabetes, Robert A. Vigersky, M.D, and Jennifer McVean, M.D., Medical Affairs Director, Medtronic Diabetes on June 4 at 9 a.m. about the robust scientific session line-up presented by Medtronic. Online registration available to non-conference attendees.
• Exhibit Booth featuring interactive components focused on diabetes technology, clinical outcomes, and support offerings for healthcare professionals and patients. Booth Presentations will include:
  • “How smart insulin pens are transforming MDI therapy: Perspectives from our R&D clinical expert” on June 4 & 5 at 11 a.m. CT by Madison Smith, Ph.D., R.N., CDCES.
  • Infusion set innovation: Meet the experts on the Medtronic Extended Infusion Set” on June 4 & 5 at 1:45 p.m. CT by Sarnath Chattaraj, Ph.D.
• Product Theatre: “Optimizing insulin therapy – stories from around the world” on Saturday, June 4 at 12:30 p.m. CT featuring Pratik Choudhary, MBBS, FRNP, M.D., University of Leicester, Greg Forlenza, M.D., MS, Children’s Hospital Colorado, Nana-Hawa Yayah Jones, M.D., Cincinnati Children’s Hospital, Jennifer McVean, M.D.
• Innovation Suite (HCP Only) highlighting Medtronic future therapy concepts and providing the opportunity for HCPs to share feedback on June 4 - 6 from 10:00 – 4 p.m. CT.

About the Diabetes Business at Medtronic (www.medtronicdiabetes.com) 
Medtronic is working together with the global community to change the way people manage diabetes. The company aims to transform diabetes care by expanding access, integrating care and improving outcomes, so people living with diabetes can enjoy greater freedom and better health. 

For more information, contact:

Contacts:
Kendra Cassillo
Public Relations
+1-818-576-5611

Ryan Weispfenning
Investor Relations
+1-763-505-4626